Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree and once I saw the CEO buy I doubled what he bought and just waited for news to hit.
Junk or not junk, If calling a stock JUNK because it makes US money... THEN I WISH FOR THEM ALL TO BE JUNK.
Maybe you should read todays news.
Hmmm Maybe my next play... Nice insider buys recently.
CNIT: Insider Buys/Sells (?)
.
Insider Position Date Trades Shares Trade Price ($) Change (%) Details
Lin Jiang Huai President and CEO, 10% Owner 2012-07-11 Buy 18,600 $0.98 3.06 view
Lin Jiang Huai PRESIDENT AND CEO, 10% Owner 2012-07-09 Buy 3,565 $1 1 view
Lin Jiang Huai President and CEO, 10% Owner 2012-07-05 Buy 6,031 $1 1 view
Lin Jiang Huai President and CEO, 10% Owner 2012-06-29 Buy 15,450 $1 1 view
Lin Jiang Huai President and CEO, 10% Owner 2012-06-26 Buy 10,293 $1 1 view
Lin Jiang Huai President and CEO, 10% Owner 2012-06-22 Buy 13,926 $1 1 view
Lin Jiang Huai PRESIDENT AND CEO, 10% Owner 2012-06-20 Buy 23,350 $1 1 view
Lin Jiang Huai PRESIDENT AND CEO, 10% Owner 2012-06-13 Buy 45,436 $0.95 6.32 view
Nothing is better then a day when everyone makes some serious bank!
very strong close, Gap up in the AM
lol I had my trigger at $1.03 $1.04 but was waiting for $1 lol. All good made some nice $$$ today!
ANTH Making some nice EOD movement.
Very strong EOD buying going on,Congrats to everyone that bought and sold and to those that are still holding!
Better to let the day traders dump today so we can start a new run soon.
Who knows partner, I will be back in and if it starts to run again I will be glad to pay more. Solid play here imo! Let's all make some bank.
All in All happy for those that got in not to long ago at $.80 and those that got in last week.
Always trade smart and dont fall for it, But once my stop loss got triggered I have to find a new entry. We could have ran harder imo passed $1.24 but like i said some day traders sold that bought in at the low today. Anyhow I like this play and will reenter at $1.03 or when the next run starts.
lol your telling me that? lol I been in this for a few weeks partner. I made bank today and looking to reenter. Why do you think I bought into this a few weeks ago when insiders were loading the boat?
Day traders killed the run today, We could have ran harder then $1.24 but once the call went out that some big day traders were selling everyone else started to panic sell. $1.03 my target to get in right now.
After this week yes, Still waiting for the end of day flippers to sell.
Not yet, waiting for $1
It went up way to fast and a ton of day traders got in. Lets see where the selling stops. We need a healthy correction might see it at $1
Waiting for reentry at $1-$1.02
day traders are dumping right now and wont hold this overnight.
That wont happen. Maybe $.90ish
Iam out. Stop loss triggerd. Will wait for a reentery.
ANTH all sold. Stop loss triggerd. Will wait to renter.
Even better news. Pps is going to recover I see $2 soon. We are still waiting news on how the conference went this past weekend.
Anth even better news
Big money coming into play now. News today is huuuuugeee for the future of the company.
ANTH run baby run... stock is starting to make it's reversal back toward $$$$$
The news today should start a nice reversal for this stock. Insiders bought for a reason.
They bought at .76
I got in last week and holding for long term play. insiders started buying so I figured I should to!
Now we know why insiders where buying.
This is a long term hold for me, I can see us trading $3 soon with more good news.
Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Pha...
Date : 07/16/2012 @ 8:45AM
Source : PR Newswire
Stock : Anthera Pharmaceuticals, Inc. (MM) (ANTH)
Quote : 0.855 0.1447 (20.37%) @ 10:23AM
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced the final set of clinical data from the Phase 2b PEARL-SC study in patients with systemic lupus erythematosus.
Final data from the PEARL-SC clinical study with 200mg weekly blisibimod suggest sustained and greater treatment effects versus placebo utilizing 6, 7, and 8-point improvements in the SELENA-SLEDAI disease-scoring index (Table 1). In the predefined population of patients with severe disease who were also taking corticosteroids, the SRI-8 treatment benefit in the 200mg weekly blisibimod cohort was seen as early as week eight and achieved statistical significance starting at week 16 (35.4% blisibimod response versus 17.0% placebo response, p=0.04) through the 24 week endpoint (41.7% blisibimod response versus 10.4% placebo response, p10) and Receiving Corticosteroid therapy at baseline
4 Reasons To Buy Anthera Pharmaceuticals
Anthera Pharmaceuticals (ANTH) is a pharmaceutical company focused on the development and marketing of products to treat serious illnesses, including cardiovascular and autoimmune diseases.
Anthera's product portfolio currently consists of a potential product in Phase IIb:
- Blisibimod targets elevated levels of B-cell activating factor (BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren's Syndrome, Graves' Disease and others.
Based on positive results in the Phase Ia and Ib clinical studies, as well as recent validation in multiple late-stage clinical studies of the role of BAFF in lupus, the company has initiated the PEARL-SC, the Phase IIb study of Blisibimod, for the treatment of Systemic Lupus Erythematosus. PEARL-SC is a randomized, double-blind, placebo-controlled, Phase IIb clinical study that will enroll approximately 540 patients in up to 90 centers in 12 countries. Patients will be randomized into three active treatment arms and one placebo treatment arm for a minimum of 24 weeks. the primary endpoint of the PEARL-SC study is clinical improvement at 24 weeks in the SLE responder index, a recently recognized FDA endpoint for demonstrating clinical efficacy.
I find at least 4 reasons to buy the stock currently
1. Phase IIb Blisibimod results
Anthera Pharmaceutical has recently presented the results of the Phase IIb on their studies for the treatment of systemic lupus erythematosus. There was a misunderstanding in the market of these results and the shares fell to $0.6 marking a new minimum of 52 wk.
Next, a comparison among the data of Blisibimod as well as the data provided to Benlysta of Human Genome Sciences, Inc (HGSI) and GlaxoSmithKline (GSK) is established in the following charts:
Table 1: Response rates for 200mg weekly subcutaneous blisibimod versus placebo
Endpoint
(Subgroup)
12 Week Response
Placebo / Active
16 Week Response
Placebo / Active
20 Week Response
Placebo / Active
24 Week Response
Placebo / Active
SRI-5
(mITT*)
27.1% / 29.3%
26.8% / 34.8%
31.6% / 44.6%
35.3% / 43.5%
SRI-5
(Moderate*)
24.1% / 30.0%
29.3% / 36.0%
31.0% / 44.0%
34.5% / 48.0%
SRI-5
(Severe*)
27.7% / 37.5%
34.0% / 41.7%
36.2% / 52.1%
40.4% / 54.2%
* mITT: Lupus, SELENA/SLEDAI > 6, seropositive
* Moderate Subgroup: Lupus, SELENA/SLEDAI > 8, seropositive, receiving steroids
* Severe Subgroup: Lupus, SELENA/SLEDAI > 10, seropositive, receiving steroids
(Source)
Table 2: Benlysta Percentage of patients meeting Primary endpoint of SRI response at week 52
(Click to enlarge)
(Source)
The data show that the effectiveness of Blisibimod (43.5% - 48.0% - 54.2%) will be increased every 4 weeks. The studies of Benlysta® have been carried out in 52 weeks. It is assumed that the effectiveness of Blisibimod that increases every 4 weeks will be superior to Benlysta® when studies will be carried out in 52 weeks.
2. The chart mark oversold
(Source)
If you look at the chart we can see that Anthera is located in extreme oversold. RSI sign is in the range 28.25 and shows a clear oversold. MACD is in the time of an onset bullish symptom.
3. Insiders are buying 220,000 shares
On 29 June 2012 the President of the company Paul F. Truex bought 20,000 shares at an average price of $0.76.
The same day Christopher S. Henney's bought 200,000 shares at an average price of $0.7493.
4. Analyst price target $4.
On 28 June 2012 the Deutsche Bank analysts reiterated the recommendation for "buy" in Anthera with a target price of $4.
On 9 July 2012 the analysts of Canaccord Genuity reiterated the recommendation to "buy" in Anthera Pharmaceutical. Its target price is $3.
ANTH Analyst Stocks Recommendations
(Source)
Conclusion:
The shares of Anthera pharmaceuticals will surely go to the range of $2.00 - $2.5 before September. As I wrote in another article the company may be of interest to pharmaceutical multinationals. I might take a small speculative position in the stock this week.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
http://seekingalpha.com/article/723171-4-reasons-to-buy-anthera-pharmaceuticals
Loaded the boat here last week, More news to come imo.. Easy buyout target.
Buy on what rumor? There is no rumor other then the 2% that commons are getting offered.... THE company has 0 assets and is going to be a shell company...
I have seen the charts, We are dealing with a judge. They need facts, They go by by speculation or maybe or I think so... The only FACT I have seen not from your work but from an SEC filing was Robert ellis shorting the stock. anyhow I am not a judge but the emails from EK standout more then charts. Judge is going to look at it and not know what to think of it.
And BTW there is no proof that inside trading was going on, WE do not have any of that.
Unless we get an EC we are going to have to rely on the SEC and other agency's to pursue the BOD. We dont have the power to ask the judge if we can go on a digging fact finding mission. We dont have anything other then what EK has said in those emails regarding the fraud that took place. This case is only as strong as the judge and the trustee. If the trustee wants to dig to see if the BOD or the company is hiding some more of the companies assets then he will, if not and he chooses not to then we are scwerd and will be hoping for other government agency's that have more power to do something.
I have not seen ANYONE or any SHAREHOLDER FILE ANY MOTION in court asking for an EC to be formed.... That imo should have been done long ago.
There is no reason for it to run because commons will get 2% of whatever the OS will be. If the OS is 100,000,000 we get 2% of it.
Well THOSE that vote YES for the plane will get shares, those that vote NO wont.
Vote yes, you grant them releases and get 2%..You will be left out of any future claims against the company if any and also a class action suit if one gets approved.
Let's not take all the credit now.....
It does not matter, it's simple. You vote on the plan and if you accept it you are granting the BOD releases which means you will not be able to do anything.
IF you VOTE NO...YOU GET NOTHING and can still sue the BOD or the company but you will have to do it on your own dime.
The #1 thing shareholders should be doing right now is asking the judge for EC to be formed to look into these claims that we have sent in. If the judge does not approve an EC for us then it's game over for us and there will be very little to nothing we can do. If the judge is interested by the stuff I along with "others" sent it and believes we do in fact have some type of proof to such claims as fraud then he will grant us an EC and in which will really open a can of worms for the CRO, the company, and the BK lawyer.
ORBIMED ADVISORS LLC UNLOADED ALL THE SHARES THEY OWN IN THIS STOCK
http://www.secform4.com/filings/1361103/000094787112000539.htm